Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Hdl Handle:
http://hdl.handle.net/10147/230660
Title:
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
Authors:
Wander, Seth A; Hennessy, Bryan T; Slingerland, Joyce M
Affiliation:
Braman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
Citation:
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. 2011, 121 (4):1231-41 J. Clin. Invest.
Journal:
The Journal of clinical investigation
Issue Date:
Apr-2011
URI:
http://hdl.handle.net/10147/230660
DOI:
10.1172/JCI44145
PubMed ID:
21490404
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069769/pdf/JCI44145.pdf; http://www.jci.org/articles/view/44145/pdf
Abstract:
Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathways gives us.
Item Type:
Article
Language:
en
MeSH:
Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Male; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins
ISSN:
1558-8238

Full metadata record

DC FieldValue Language
dc.contributor.authorWander, Seth Aen_GB
dc.contributor.authorHennessy, Bryan Ten_GB
dc.contributor.authorSlingerland, Joyce Men_GB
dc.date.accessioned2012-06-25T16:27:49Z-
dc.date.available2012-06-25T16:27:49Z-
dc.date.issued2011-04-
dc.identifier.citationNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. 2011, 121 (4):1231-41 J. Clin. Invest.en_GB
dc.identifier.issn1558-8238-
dc.identifier.pmid21490404-
dc.identifier.doi10.1172/JCI44145-
dc.identifier.urihttp://hdl.handle.net/10147/230660-
dc.description.abstractMammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathways gives us.en_GB
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069769/pdf/JCI44145.pdfen_GB
dc.relation.urlhttp://www.jci.org/articles/view/44145/pdfen_GB
dc.rightsArchived with thanks to The Journal of clinical investigationen_GB
dc.subject.meshAntineoplastic Agents-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNeoplasms-
dc.subject.meshPhosphatidylinositol 3-Kinases-
dc.subject.meshProtein Kinase Inhibitors-
dc.subject.meshSignal Transduction-
dc.subject.meshSirolimus-
dc.subject.meshTOR Serine-Threonine Kinases-
dc.subject.meshTranscription Factors-
dc.subject.meshTumor Suppressor Proteins-
dc.titleNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.en_GB
dc.typeArticleen
dc.contributor.departmentBraman Family Breast Cancer Institute, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.en_GB
dc.identifier.journalThe Journal of clinical investigationen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.